Research Topics
| Daniel B KramerSummaryAffiliation: Harvard University Country: USA Publications
|
Detail Information
Publications
How does medical device regulation perform in the United States and the European union? A systematic reviewDaniel B Kramer
Harvard Medical School, Boston, Massachusetts, United States of America
PLoS Med 9:e1001276. 2012..Data may be available that identify strengths and weakness of the approaches to medical device regulation in these settings...
Security and privacy qualities of medical devices: an analysis of FDA postmarket surveillanceDaniel B Kramer
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
PLoS ONE 7:e40200. 2012..These computing capabilities introduce security and privacy risks, yet little is known about the prevalence of such risks within the clinical setting...
"Just Because We Can Doesn't Mean We Should": views of nurses on deactivation of pacemakers and implantable cardioverter-defibrillatorsDaniel B Kramer
Beth Israel Deaconess Medical Center, Harvard Medical School, 185 Pilgrim Road, Baker 4, Boston, MA, 02215, USA
J Interv Card Electrophysiol 32:243-52. 2011..This study aims to identify nurses' concerns about the clinical, ethical, and legal aspects of deactivating cardiovascular implantable electronic devices (CIEDs)...
Long-QT syndromeDaniel B Kramer
Department of Medicine, Cardiovascular Division, Beth Israel Deaconess Medical Center Harvard Medical School, Boston, MA, USA
Cardiol Rev 19:217-25. 2011..In this review, the pathophysiologic, diagnostic, and prognostic features of long-QT syndromes, as well as recommendations regarding therapy, are reviewed...
Ethical and legal views regarding deactivation of cardiac implantable electrical devices in patients with hypertrophic cardiomyopathyDaniel B Kramer
Cardiovascular Institute, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
Am J Cardiol 107:1071-1075.e5. 2011..In conclusion, patients who have, or are eligible to receive, CIEDs might require improved advance care planning and education regarding the ethical and legal options for managing CIEDs at the end of life...
Ethical and legal views of physicians regarding deactivation of cardiac implantable electrical devices: a quantitative assessmentDaniel B Kramer
Cardiovascular Institute, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02446, USA
Heart Rhythm 7:1537-42. 2010..Despite the high prevalence of pacemakers and implantable cardioverter-defibrillators, little is known about physicians' views surrounding the ethical and legal aspects of managing these devices at the end of life...
An unusual cause of abnormal intrathoracic impedance in a patient with arrhythmogenic right ventricular cardiomyopathyDaniel B Kramer
Cardiovascular Institute, Beth Israel Deaconess Medical Center, Harvard Medical School Boston, Massachusetts 02215, USA
Pacing Clin Electrophysiol 34:e60-3. 2011..The strengths and limitations of intrathoracic impedance are described in the context of the physiology of pregnancy...
Deactivation of pacemakers and implantable cardioverter-defibrillatorsDaniel B Kramer
Hebrew SeniorLife Institute for Aging Research, Boston, MA, USA
Prog Cardiovasc Dis 55:290-9. 2012..The empirical literature describing stakeholder views and experiences surrounding CIED deactivation is described, along with implications of these studies for future research surrounding the care of patients with CIEDs...
Management of cardiac electrical implantable devices in patients nearing the end of life or requesting withdrawal of therapy: review of the Heart Rhythm Society 2010 consensus statementDaniel B Kramer
The Cardiovascular Institute, Beth Isreal Deaconess Medical Center, Harvard Medical School Boston, Massachusetts, United States
Pol Arch Med Wewn 120:497-502. 2010..In this article, we provide a summary of the HRS guidelines and highlight the most important features of CIED deactivation for the practicing clinician...
Development and validation of a risk score to predict early mortality in recipients of implantable cardioverter-defibrillatorsDaniel B Kramer
Beth Israel Deaconess Medical Center, Boston, Massachusetts 02446, USA
Heart Rhythm 9:42-6. 2012..Better methods are needed for identifying patients at high risk for early mortality despite ICD therapy...
Resynchronization: considering device-based cardiac therapy in older adultsDaniel B Kramer
Hebrew Senior Life Institute for Aging Research, Boston, Massachusetts Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts Division of Gerontology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts Harvard Medical School, Boston, Massachusetts
J Am Geriatr Soc 61:615-21. 2013..Informed decision-making by clinicians, policy-makers, and patients will require greater understanding of the use and outcomes of CRT in older persons...
Premarket clinical evaluation of novel cardiovascular devices: quality analysis of premarket clinical studies submitted to the Food and Drug Administration 2000-2007Daniel B Kramer
Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, MA, USA
Am J Ther 17:2-7. 2010..Manufacturers, regulators, and the clinical community should collaborate to address these study shortcomings to ensure that patients are treated with reliable, safe, and clinically useful medical devices...
Event-free survival following CRT with surgically implanted LV leads versus standard transvenous approachAmy L Miller
Department of Medicine, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts, USA
Pacing Clin Electrophysiol 34:490-500. 2011..We hypothesized that surgical procedures would be associated with increased mortality risk...
Cardiac resynchronization therapy for low-flow, low-gradient aortic stenosisYuval Konstantino
The Cardiovascular Institute, Beth Israel Deaconess Medical Center, Baker 4, 185 Pilgrim Road, Boston, MA 02215, USA
Eur J Heart Fail 12:889-92. 2010..We discuss the management of this high-operative-risk patient, who ultimately underwent upgrading of his dual chamber pacemaker to a biventricular pacemaker with significant echocardiographic, haemodynamic, and clinical improvement...
